Keyphrases
Cryoimmunotherapy
100%
Cryoablation
66%
Interleukin-12 (IL-12)
50%
Collagen Binding
33%
Lung Cancer
27%
Lung Tumor
22%
Cryo
22%
Immune Cells
16%
Tumor Cells
16%
Immune System
16%
Tumor
16%
Collagen
16%
Systemic Antitumor Immunity
11%
Novel Molecules
11%
Recurrent Tumor
11%
Patrolling
11%
Early-stage Lung Cancer
11%
Smoking Exposure
11%
Stage I Disease
11%
Effector Immune Cells
11%
Liquefied Gas
11%
Surgical Alternative
11%
Lung Cancer Patients
11%
Metastasis
11%
Surgical Resection
11%
Coin Flip
11%
Patient Recovery
11%
Attack Target
11%
Locoregional Therapy
11%
Combination Immunotherapy
11%
Liquefied Nitrogen
11%
Systemic Circulation
11%
Suppressing Cell
11%
Antitumor Immune Response
11%
Immune Stimulation
11%
Recurrence Prevention
11%
Innovative Strategies
11%
Primary Tumor
11%
Tumor Recurrence
5%
Structural Proteins
5%
Military Veterans
5%
Left behind
5%
Carcinogen
5%
Clinically Significant
5%
Immune Response
5%
Surgical Removal
5%
Adjuvant Therapy
5%
Cancer Center
5%
Cryoprobe
5%
Interleukin
5%
Hospital Stay
5%
Master Regulator
5%
Large Animal Model
5%
Occupational Exposure
5%
Cancer Therapy
5%
Survival Rate
5%
Current Treatment
5%
Lung Cancer Cells
5%
Effective Therapy
5%
Tumor Model
5%
Argon
5%
Protein Fragments
5%
Military Personnel
5%
Minimally Invasive
5%
Lung Cancer Treatment
5%
Treatment Strategy
5%
Translational Studies
5%
Medical Center
5%
State Colleges
5%
Defense Mechanisms
5%
Lung Metastasis
5%
Humanized
5%
Patient's Will
5%
Combined Method
5%
Veterinary Medicine
5%
High Risk
5%
Clinical Trial Development
5%
Medicine and Dentistry
Cryoablation
66%
Interleukin 12
50%
Lung Cancer
50%
Immunotherapy
27%
Tumor Recurrence
22%
Lung Tumor
22%
Immunocompetent Cell
22%
Metastatic Carcinoma
16%
Neoplasm
16%
Tumor Cell
16%
Treatment of Lung Cancer
11%
Systemic Circulation
11%
Immune Response
11%
Recurrent Disease
11%
Surgery
11%
Primary Tumor
11%
Immune System
11%
Adjuvant Therapy
5%
Medicine
5%
Clinical Trial
5%
Disease
5%
Occupational Exposure
5%
Carcinogen
5%
Cancer Therapy
5%
Tumor Model
5%
Survival Rate
5%
Structural Protein
5%
Interleukin Derivative
5%
Cells of the Immune System
5%
Malignant Neoplasm
5%
Cancer Cell
5%
Pharmacology, Toxicology and Pharmaceutical Science
Interleukin 12
50%
Lung Cancer
50%
Neoplasm
30%
Immunotherapy
25%
Lung Tumor
20%
Malignant Neoplasm
10%
Tumor Recurrence
10%
Interleukin Derivative
10%
Systemic Circulation
10%
Primary Tumor
10%
Recurrent Disease
10%
Metastasis
5%
Structural Protein
5%
Tumor Model
5%
Carcinogen
5%
Occupational Exposure
5%
Clinical Trial
5%
Disease
5%
Survival Rate
5%